Asia Pacific Active Pharmaceutical Ingredient Market to show Impressive Growth During the Forecast Period
Advancing healthcare industry drives the Asia-Pacific Active
Pharmaceutical Ingredient Market growth in the forecast period, 2022-2026F.
According to TechSci Research report, “Asia-Pacific
Active Pharmaceutical Ingredient Market By Method of Synthesis
(Biological v/s Synthetic) By Source (Contact Manufacturing Organizations v/s
In-House Manufacturing) By Therapeutic Application (Cardiovascular Diseases,
Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal
Disorders, Others) By Molecule Type (Small v/s Large) By Potency (Low v/s High)
By Drug Type (Innovator v/s Generics) By Country, Competition Forecast &
Opportunities, 2026”, the Asia Pacific active
pharmaceutical ingredient market is projected to grow on the backbone of rapidly
evolving research and development sectors of healthcare industry. The Asia
Pacific active pharmaceutical ingredient market is expected to show an impressive
CAGR rate in the forecast period, 2022-2026. Moreover, the governmental schemes
and regulation toward the development and extended research for the more
efficient and viable active pharmaceutical ingredient is aiding the growth of
the market. With the market players involved in the self-development of the
drugs, role of FDA and drug authority bodies are actively regulating the
quality of the pharmaceutical products.
The Council of Scientific and Industrial Research (CSIR), in
collaboration with coal and petroleum industries in India are actively working
for the pharmaceutical component that would make up the main therapeutic
component of the drugs. They have a list of 56 APIs that are being prioritized
for the drugs, made in India. This initiative will aid to the country’s
non-dependency on the neighboring countries like China for the supply of APIs
as well as support the growth of the Asia Pacific active pharmaceutical
ingredient market in the upcoming five years.
Browse over XX
market data Figures spread through 110 Pages
and an in-depth TOC on "Asia Pacific Active Pharmaceutical
Ingredient Market"
https://www.techsciresearch.com/report/asia-pacific-active-pharmaceutical-ingredient-market/7676.html
The Asia Pacific active pharmaceutical ingredient
market is segmented by method of synthesis, source, therapeutic application,
molecule type, potency, drug type, competitional landscape, and regional
distribution. Based on source, the market is divided between contact
manufacturing organizations and in-house manufacturing. In-house manufacturing
is anticipated to hold the larger revenue shares of the market and assert its
dominance over the market on the account of easier availability of raw material
in the manufacturing units as well as their compatibility with the drug production.
Market players have actively taking initiatives for the in-house manufacturing
and thereby supporting the growth of the market in the next five years.
Although, contact manufacturing is expected to register the fastest growing
CAGR in the upcoming years, since Asian countries like India, China are
actively involved in the contract based production of API. In the year, 2017
Eisai
Pharmaceuticals invested over USD 9.32 million to install manufacturing
equipment for API production in India.
Based on method of synthesis, the market is further
bifurcated into biological and synthetic methods of synthesis. Synthetic
methods of synthesis are anticipated to hold the larger revenue shares of the
market in the upcoming five years on the account of availability of the raw
materials and easier protocols for the synthesis of active pharmaceutical
ingredients. Also, increasing presence of the soon to be off-patent molecules
are expected to further boost the market growth in the next five years of
forecast.
Holding largest shares of the Asia Pacific active
pharmaceutical ingredient market revenue, market players like Cipla Limited,
Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Symbiotica Speciality Ingredients
Sdn. Bhd., ScinoPharm Taiwan Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd.,
Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Ltd., AbbVie Inc., AstraZeneca plc, GlaxoSmithKline plc, Sanofi
S.A., Lupin Limited, Nanjing Pharmaceutical Factory Co. Ltd., among others are actively
involved with the research and development process of the Active Pharmaceutical
Ingredients in the region. Countries like India, China, Japan, have dedicated
research labs for the advanced products development and consistent product
modifications. China is the largest market followed by India, Japan, and
Taiwan. Research and technological advancement for the high potency active
pharmaceutical ingredient would be the best strategy for the new market players
entering the market. Other strategic recommendation can be collaboration and
inter-dependency with the existent market giants. The market is well developed
and presence of multiple market players in the major economies of the region
are actively influencing the market growth.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7676
Customers can also request for
10% free customization on this report.
“China market is the
most promising market in terms of the largest amount of revenue shares the
country is generating with its improving healthcare industry. Active
pharmaceutical ingredient has second largest market in India and probably the
fastest growing market in the future five years of forecast. In the upcoming
five years, the country is expected to be able to overcome its dependency in
the neighboring countries for the drug dependency. New market players would
gain from the legitimate collaborations with the authoritative bodies like
CSIR. It is advisable to focus on the extensive research and development of
higher potency drugs that can overcome the countries dependencies on the
neighboring countries. Taiwan is a budding market for the active pharmaceutical
ingredient in the future five years, the availability of the raw material and
cheaper labor would help,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based Asia Pacific management consulting firm.
“Asia-Pacific Active
Pharmaceutical Ingredient Market By Method of Synthesis (Biological v/s
Synthetic) By Source (Contact Manufacturing Organizations v/s In-House
Manufacturing) By Therapeutic Application (Cardiovascular Diseases,
Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal
Disorders, Others) By Molecule Type (Small v/s Large) By Potency (Low v/s High)
By Drug Type (Innovator v/s Generics) By Country, Competition Forecast &
Opportunities, 2026”,
has evaluated the future growth potential of Asia Pacific active pharmaceutical
ingredient and provides statistics & information on market size, structure
and future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Asia Pacific active
pharmaceutical ingredient.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/